Navigation Links
Fixed Dosed Combination Agents and Novel Antihypertensives Are Expected to Face Tougher Formulary Restrictions
Date:4/28/2009

Longitudinal Data Trends Suggest These Agents Will Face Greater Use of Step Therapy Restrictions and Less Access on Tier 2 on Commercial Health Plans, According to a New Report from HealthLeaders-InterStudy and Fingertip Formulary

NASHVILLE, Tenn. and GLEN ROCK, N.J., April 28 /PRNewswire/ -- HealthLeaders-InterStudy and Fingertip Formulary find that fixed dosed combination agents and novel antihypertensives are expected to face tougher formulary restrictions. According to the new Formulary Forum report entitled Formulary Advantages in Hypertension: Past and Future Shifts in Tier Placement of Angiotensin II Receptor Antagonists, Single Pill Fixed-Dose Combinations and Novel Agents, step therapy restrictions are becoming more common in commercial health plans across all classes of antihypertensives, suggesting fixed dosed combination agents and novel antihypertensives will face less access on Tier 2 on commercial health plans.

The report notes that although the number of commercial health plans placing step restrictions on angiotensin II receptor antagonists is relatively stable, a growing number of covered lives are subject to a step therapy restriction. Meanwhile, the number of commercial health plans placing prior authorization restrictions on antihypertensives has decreased over the past year.

"By and large, more agents are subject to prior authorization restrictions with more commercial health plans than are subject to step therapy restrictions, but we are seeing step therapy restrictions becoming increasingly common," said Michael Malecki, Ph.D., product manager, Formulary Forum. "The changing landscape of formulary controls in the hypertension market means that managed care marketing and sales analytics groups must track this newly-important performance metric."

About Formulary Advantages in Hypertension: Past and Future Shifts in Tier Placement of Angiotensin II Receptor Antagonists, Single Pill Fixed-Dose Combinations and Novel Agents

The new Formulary Forum report is based on a survey of 50 pharmacy directors who control national, regional and state-level managed care organizations, as well as historical formulary data from Fingertip Formulary. Answers were segmented by type of plan to illustrate variances in strategy by size of plan. The easy-to-use PowerPoint format allows easy visualization of data and easy incorporation of material into presentations.

About Fingertip Formulary

Fingertip Formulary (www.FingertipFormulary.com), the leading provider of access to and insight into formulary data in the United States, offers comprehensive formulary data covering commercial, Medicaid, Medicare and PBM plans, among others. The company offers a variety of unique data and marketing solutions for the pharmaceutical industry, consultants and healthcare providers that provide access to and insight into formulary data. Fingertip Formulary is a Decision Resources, Inc. company.

About HealthLeaders-InterStudy

HealthLeaders-InterStudy, a Decision Resources, Inc. company, is the authoritative source for managed care data, analysis and news. For more information, please visit www.HL-ISY.com.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Both HealthLeaders-InterStudy and Fingertip Formulary are Decision Resources, Inc. companies. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.


'/>"/>
SOURCE HealthLeaders-InterStudy
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Conseco Completes Divestiture of Old Block of Fixed and Equity-Indexed Annuities
2. New Human Services Website Details Economic Importance of Providers, Warns of Looming Crisis if System is Not Fixed Immediately
3. AAHSA Survey and Certification Task Force: The System Is Broken and Cant Be Fixed
4. Nursing Home Task Force Says, The System Is Broken and Cant Be Fixed
5. New Study Provides Benchmarks for Fixed-Dose Combination (FDC) Drug Development
6. AARP Responds to Senator Grassley, Conducts Comprehensive Review of Marketing of Fixed Benefit Indemnity Products
7. Best Practice Database Provides Benchmarks for Fixed-Dose Combination (FDC) Drug Development
8. Allsup Finds Healthcare Costs Consuming Larger Part of Fixed Incomes
9. New Fixed Blade Axial dc Fan From NMB
10. 70% of Contact Lens Cases are Contaminated and Nearly 1 in 4 are Never Replaced - a Serious Problem Eye Doctors Want Fixed, WatchDog Group Reports
11. Promising drug combination may help those with ocular melanoma that has spread
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... Raton, FL (PRWEB) , ... January 20, 2017 , ... ... development, announced it attended the January ECRM trade show to continue the marketing and ... advanced vitamin C supplement, known for providing 400 percent better absorption than traditional vitamin ...
(Date:1/20/2017)... ... January 20, 2017 , ... Lice Troopers, the lice ... in families with school-aged children since the holiday season. , “It happens every ... their families, sharing hugs and taking photos, which is the head-to-head gateway that lice ...
(Date:1/20/2017)... Boca Raton, FL (PRWEB) , ... January 20, 2017 , ... ... highest level of nutritional and bodybuilding supplements, announced it attended the January ECRM trade ... a respected bodybuilder and nutritional scientist who was determined to create a line of ...
(Date:1/20/2017)... ... January 20, 2017 , ... "TransFlare 4K Mystique comes with 44 ... Cut Pro X," said Christina Austin - CEO of Pixel Film Studios. , ... Dragon Sensor,TransFlare 4K Mystique lens flare and light leak transitions have a very high-dynamic ...
(Date:1/20/2017)... ... January 20, 2017 , ... “Mary Magdalene: Grace is ... life of the woman who witnessed Jesus Christ firsthand. “Mary Magdalene: Grace is Greater ... spent her career as an educator interacting with countless women who had little knowledge ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... Jan. 19, 2017 Germany ... GlobalData,s new report, "Germany Cataract Surgery Devices Market ... Germany Cataract Surgery Devices market. The report provides value, ... average prices (USD) within market segements - Phacoemulsification Equipment ... provides company shares and distribution shares data for each ...
(Date:1/19/2017)... YORK , Jan. 19, 2017 The ... provides understanding and access to partnering deals and agreements ... - Trends in partnering deals - Top deals by ... stage of development, technology type The report provides ... entered into by the world,s leading healthcare companies. ...
(Date:1/19/2017)... , Jan. 19, 2017 Report Details ... ... for Leading Companies – our new study reveals trends, ... issues and events affecting the Alzheimer,s disease therapeutics and ... answer these key questions: - How is the Alzheimer,s ...
Breaking Medicine Technology: